Levels Of Resistin And Visfatin In Patients With Metabolic Syndrome

1. Galik S, Oakhill J, Steinberg G. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129-39.10.1016/j.mce.2009.08.01819723556Search in Google Scholar

2. Karastegiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1-2):69-78.10.1016/j.mce.2009.11.01119948207Search in Google Scholar

3. Koleva D, Orbetzova M, Atanasova P. Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med. 2013;55(11):25-32.10.2478/folmed-2013-000223905484Search in Google Scholar

4. Deng Y, Scherer P. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:E1-E19. doi: 10.1111/j.1749-6632.2010.05875.x.10.1111/j.1749-6632.2010.05875.x307541421276002Search in Google Scholar

5. Dogru T, Sonmez A, Tasci I, Bozoglu E. Yilmaz MI, Gene H. at al. Plasma resistin levels in patients with newly diagnosed untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76 (1):2-7.10.1016/j.diabres.2006.07.03116956691Search in Google Scholar

6. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007;156(2):279-84.10.1530/eje.1.0233817287419Search in Google Scholar

7. Utzschneider K, Carr D, Tong J, Wallace T, Hull R, Zrika S at al. Resistin is not associated with insulin sensitivity or metabolic syndrome in humans. Diabetologia. 2005;48(11):2330-3.10.1007/s00125-005-1932-y16143861Search in Google Scholar

8. Fukuhura A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;5708(307):426-30.10.1126/science.109724315604363Search in Google Scholar

9. Saddi-Rosa P, Olivera C, Giuffrida F, Reis A. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010; 26;2:21. doi: 10.1186/1758-5996-2-21.10.1186/1758-5996-2-21285782520346149Search in Google Scholar

10. Christov Vl, Gocheva N, Petkova M, Zaharieva S, Tankova Tz, Orbetzova M, et al. A consensus of the Bulgarian Institute Metabolic Syndrome. Nauka Endocrinologia. 2010;2:3-70. (in Bulgarian)Search in Google Scholar

11. World Health Organization. Definition and diagnosis of Diabetes Mellitus and intermediate Hyperglycaemia. Report of WHO/IDF Consultation. Geneva, World Health Org. 2006.Search in Google Scholar

12. Tota-Maharaj R, Defilippis A, Blumenthal R, Blaha M. A practical approach to the metabolic syndrome: review of current concepts and management. Curr Opin Cardiol. 2010;25(5):502-12.10.1097/HCO.0b013e32833cd47420644468Search in Google Scholar

13. Borissova A-M, Kovatcheva R, Shinkov A, Atanassova I, Vukov M, Aslanova N et al. Prevalence and features of the metabolic syndrome in unselected bulgarian population. Endocrinologia. 2007;2:68-77. (in Bulgarian)Search in Google Scholar

14. Rayanova G, Ganeva S, Todorova K, Lukanov T, Gecheva S. Disorders of the carbohydrate metabolism in patients with metabolic syndrome. Endocrinologia. 2014;3:139-43. (in Bulgarian)Search in Google Scholar

15. De Luis DA, Gonzalez SM, Conde R, Aller R, Izaola O, Primo D. lack of association of serum resistin levels with metabolic syndrome criteria in obese patients. Clin Biochem. 2012;44(16):1280-3.10.1016/j.clinbiochem.2011.09.00221939645Search in Google Scholar

16. Silha V, Kresk M, Skrha J, Sucharda P, Nyomba B, Murphy L. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149(4):331-5.10.1530/eje.0.149033114514348Search in Google Scholar

17. Ebtesam DL-S and Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18(1):12-29.10.1186/2047-783X-18-12365586723634778Search in Google Scholar

18. Rabe K, Lehrke M, Parhofer K, Broedi U. Adipokines and insulin resistance, Mol Med. 2008; 14 (11-12): 741-751.10.2119/2008-00058.Rabe258285519009016Search in Google Scholar

19. Tan H, Zhong M, Gomg H, Wang S, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome. Clinical Endocrinology. 2008; 6(69):878-884.Search in Google Scholar

20. Esteghamati A, Morteza A, Zandieh A, Jafari S, Rezaee M, Nakhjavani M. The value of visfatin in the prediction of metabolic syndrome: a multifactorial analysis. J Cardiovasc Tnansl Res. 2012;5(4):541-6.10.1007/s12265-012-9373-822585407Search in Google Scholar

21. Vasilescu R, Ifrim S, Trigoviste C. Relationship between plasma adipokines, inflammation, insulin resistance and subclinical atherosclerosis in newly diagnosed type 2 diabetes. Journal of Diabetes Mellitus. 2011;1(2):17-25.10.4236/jdm.2011.12004Search in Google Scholar

22. Rasouli N, Kern P. Adipocytokines and metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93(11):S64-S73.10.1210/jc.2008-1613258575918987272Search in Google Scholar